International Journal of Environmental Sciences
ISSN: 2229-7359
Vol. 11 No. 19s, 2025
https://www.theaspd.com/ijes.php

Proper Disposal Of Investigational Products In Clinical Research: Regulatory Framework, Operational Guidance And Environmental Stewardship

Sabarish Sachithanandan J[1*], Rejethashri K[1], Raksana Sivakumar[1], Shruti. V. Iyer[1], Swapnil Suresh Patil[1]

[1*]Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, The Nilgiris, Ooty, Tamil Nadu, India.
*Corresponding Author: Sabarish Sachithanandan J
*Email: sabsachith88@gmail.com

Abstract
Proper management and disposal of investigational products (IPs) in clinical trials is essential for participant safety, data integrity, regulatory compliance (Good Clinica Practice & Good Manufacturing Practice), and environmental sustainability. This review synthesizes evidence from environmental science, clinical trial guidelines, and biomedical waste management literature to provide a holistic framework for cradle-to-grave stewardship of IPs. Key topics include environmental risks of pharmaceutical pollution, global regulatory guidance, operational procedures for return and destruction, documentation practices, and strategies to minimize ecological harm with gaps and future directions.

1. INTRODUCTION

Investigational products (IPs), including medications, biologics, and devices, are central to clinical trials and must be managed via a "cradle-to-grave" model-tracking each unit from manufacture through use, return or destruction. This ensures participant safety, data validity, and compliance with Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP).[1,2] At the same time, unreturned or improperly discarded IPs can enter the environment and persist as pharmaceutical residues, posing ecological and health risks. [3]
Environmental Persistent Pharmaceutical Pollutants (EPPPs) can occur at nano-gram per litre concentrations and disrupt aquatic ecosystems. Even low concentrations of estrogens, beta-blockers or antibiotics may feminize fish, lower fertility, or promote antimicrobial resistance.[4,5] Thus, clinical research entities bear responsibility not only for human safety but environmental stewardship.

2. ENVIRONMENTAL RISKS ASSOCIATED WITH IMPROPER DISPOSAL OF IPS

2.1 Routes of Pharmaceutical Pollution

Pharmaceuticals enter the environment via multiple pathways: human excretion, improper disposal (flushing or trash), hospital effluent, industrial discharge, landfill leachate and agricultural runoff. [6,7] Conventional wastewater treatment plants often lack the advanced filtration stages needed to remove Pharmaceutical and Personal Care Products (PPCPs), facilitating discharge into rivers and coastal waters.[8]

2.2 Ecotoxicological Effects

Decades of evidence show pharmaceuticals in effluents at ng/L to low-µg/L levels can induce endocrine disruption, behavioural changes, reproductive failure and mortality in fish and invertebrates. For example, ethinylestradiol can cause vitellogenin production and masculinization in male fish at concentrations < 1 ng/L. Propranolol and gemfibrozil have also been shown to impair egg production or alter testosterone levels in fish species.[9,10] Antibiotic residues contribute to bacterial resistance in aquatic and terrestrial organisms.[11]

2.3 Human Health Concerns

Although direct human exposure via drinking water is still under investigation, evidence links long-term presence of pharmaceutical residues to respiratory diseases, cancer risks, neurological effects, and transmission through the food chain-particularly in low- and middle-income regions where groundwater may be contaminated. [12,13]

Works show that in India and other regions inadequate treatment or open burning of pharmaceutical waste contaminates soil and water, leading to antimicrobial-resistant bacteria, genetic pollution, and impacts on human and animal health. [14,15] In South Asia, veterinary diclofenac residues contributed to catastrophic declines in vulture populations.[16] Impacts accumulate through trophic levels, affecting agriculture and food safety.

3. REGULATORY AND INTERNATIONAL GUIDANCE FRAMEWORK

3.1 ICH E6(R3) – Good Clinical Practice, January 2025

The ICH E6(R3) guideline mandates accountability and documentation of all investigational product activities, including destruction. It requires sponsors to define procedures for shipping, receipt, storage, return, reconciliation, and destruction of IPs, as well as chain-of-custody documentation and independent oversight.[17,18]

3.2 WHO Guidelines for Safe Pharmaceutical Waste Disposal

WHO's framework details hierarchy for pharmaceutical waste: source reduction, safe segregation, secure transport, treatment methods (incineration, autoclaving, chemical disinfection), and capacity building. It emphasizes training, monitoring and documentation. [19]

3.3 National Regulations and Examples

- **India**: Biomedical Waste Management Rules (2016, amended 2018) enforce colour-coded segregation, barcoding and recording of pharmaceutical and biological wastes, requiring licensed treatment facilities.
- **European Union (EU)**: Under Directive 2004/27/EC, member states must operate take-back systems for expired or unused medicines; Germany mandates high-temperature incineration, while France uses pharmacy-based collection (Cyclamed).
- **United States of America (USA): Food and Drug Administration** (FDA) and Environmental Protection Agency (EPA) encourage drug take-back programs; the Controlled Substances Act and Drug Enforcement Administration (DEA) rules regulate destruction of controlled substances. Periodic National Drug Take-Back Days and mail-back envelopes are encouraged for overflow disposal.[20,21,22]

4. OPERATIONAL PROCEDURES FOR DISPOSAL IN CLINICAL TRIALS

4.1 Planning & SOP Integration

At trial initiation, sponsors must include disposal policies in clinical supply plans and standard operating procedures (SOPs). SOPs should define roles and responsibilities for sponsors, sites, pharmacies, Quality Assurance (QA), and external vendors, including environmental considerations like minimizing hazardous waste.

4.2 Participant Return Procedures

Participants should be instructed to return unused or partially used IPs and empty packaging. Return kits must be validated, especially for temperature-sensitive biologics, and include chain-of-custody documentation. Proper counselling increases return compliance and reduce environmental losses.

4.3 Quarantine and QA Authorization

Returned IPs must be quarantined upon receipt pending QA review. QA confirms reconciliation of product and batch numbers, verifies chain-of-custody logs, and authorizes destruction. This ensures accountability and audit-readiness.[23]

4.4 Destruction Approaches

Destruction should be performed using validated methods:

- **High-temperature incineration** (900–1,300 °C) with emission controls to prevent dioxins/furans.
- **Autoclaving or chemical neutralization** for biologically hazardous or liquid waste.
- **Microwave, inertization or on-site treatment** where permitted and validated.

Destruction must be witnessed by independent staff and documented. Certificates of Destruction (CoDs) must detail product identity, batch numbers, quantity, date, method, and signatures of personnel involved. [24,25,26]

4.5 Segregation, Containment and Transport

Waste should be segregated into pharmaceutical, sharps, biological and general categories using colour-coded containers per WHO or national guidelines. Sharps containers must be puncture-resistant and labelled. Transport to destruction facilities should comply with local hazardous material and environmental laws.[27]

4.6 Documentation & Certification

All destruction events must be documented in a certified destruction form or Drug Accountability Record (DAR). Certificate of Destructions (CoDs) must be stored in the Trial Master File. Chain-of-custody logs track every unit to ensure none are unaccounted for. Dual signatures (e.g. pharmacy staff and witness) should validate each destruction instance.[28,29,30]

5. ENVIRONMENTAL STEWARDSHIP AND WASTE MINIMIZATION

5.1 Forecasting and Inventory Control

Digital track-and-trace systems and centralized supply forecasting can reduce over-supply and expiry-related waste. Minimizing surplus leads to fewer returns and reduced environmental exposure.

5.2 Take-Back and Stewardship Programs

Regulated take-back programs (like France's Cyclamed, US DEA mail-back, or county stewardship ordinances in California) help collect unused pharmaceuticals outside clinical settings-but clinical sponsors can adopt similar programs for trial IPs post-study closure.[31,32,33]

5.3 On-Site Treatment & Reverse Logistics

Decentralized treatment options like pharmacist-operated incinerators or microwave-based systems can reduce transport needs and emissions, although regulatory validation is required. Efficient reverse logistics systems using route optimization and optimized site selection can improve sustainability.[34,35,36]

5.4 Stakeholder Education

Surveys show that pharmacists and healthcare professionals often lack knowledge on proper drug disposal; most advise patients to throw expired medicines in household bins. Educational interventions, even brief ones, significantly improve disposal practices. Pharmacists, as trusted healthcare providers, are key educators.

6. CHALLENGES, GAPS AND RESEARCH NEEDS

6.1 Infrastructure and Enforcement

Many regions, especially in low- and middle-income countries, lack certified waste treatment vendors or sufficient regulation enforcement. Local infrastructure deficits remain a critical barrier to compliance.[37,38,39,40]

6.2 Inter-Regulatory Misalignment

GCP/GMP frameworks for trial conduct may not align fully with environmental or customs/deport regulation, especially in multi-national trials. Clear SOPs are needed to define QA-GCP vs QA-GMP responsibilities and jurisdictional boundaries.[41,42]

6.3 Financial and Logistical Burden

Reverse logistics, secure transport, return kits, and witness-based destruction add cost and complexity, especially for small trials or in remote settings. Yet these are critical investments for environmental and regulatory compliance.

6.4 Data Deficits on Environmental Outcomes

Empirical research on fate and transport of IP specific contaminants versus over-the-counter or common pharmaceuticals is limited. More modelling and field studies are needed to quantify environmental risks associated with IP disposal and evaluate treatment technologies in real-world settings.[43,44,45,46]

7. RECOMMENDATIONS AND BEST PRACTICES SUMMARY

Process Area	Best Practice
Planning & SOPs	Embed disposal protocols at protocol design, define roles & responsibilities
Forecasting	Use digital systems to minimize IP overstock and expiry-related waste
Participant Returns	Counsel participants; use validated kits; track temperature for biologics
Accountability & QA	Chain-of-custody logs; barcode tracking; QA reconciliation on returns
Quarantine & Authorization	Quarantine returned IPs; QA sign-off prior to destruction
Destruction Methods	Incineration, autoclave, or validated chemical/microwave processes based on waste type
Segregation & Transport	Color-coded containers; proper transport packaging; regulatory compliance
Documentation & Certification	DAR log; CoDs; dual signatures and audit-ready records
Stewardship & Recycling	Consider take-back, reuse programs, on-site treatment options
Education & Training	Train site staff, pharmacists, participants on disposal policies and risks

8. Extended Discussion: Environmental Framework Integration

8.1 Lifecycle Approach in Pharmaceutical Development

Environmental impact arises at each stage-from manufacturing to disposal. Lifecycle assessments suggest early mitigation (e.g. green chemistry, waste reduction in production) results in significant benefit. Industry insights reveal limited current action on end-of-life disposal, highlighting need for comprehensive circular strategies.[47,48,49,50,51]

8.2 Circular Economy and Extended Producer Responsibility

Approaches like eco-pharmacovigilance and Extended Producer Responsibility (EPR) require pharmaceutical producers to finance or operate disposal systems. These models promote shared accountability across the supply chain and reduce environmental release from both clinical and consumer settings.

8.3 Regulatory Evolution

Regulatory agencies (e.g. EMA, US EPA, WHO) are moving toward integrating environmental risk assessment into drug approval and post-marketing surveillance. The EU Water Framework Directive now includes pharmaceuticals as priority pollutants; ICH E6(R3) emphasizes inclusion of disposal processes in GCP guidelines. [52,53,54,55,56]

9. FUTURE DIRECTIONS AND RESEARCH OPPORTUNITIES

- **Effectiveness studies**: Validate environmental outcomes of different disposal technologies (autoclave vs incineration vs advanced oxidation).
- **Behavioural research**: Evaluate the impact of educational interventions and trial policies on return compliance and environmental outcomes.
- **Policy analysis**: Examine regulatory alignment across jurisdictions and propose harmonized guidelines for international trials.
- **Innovation**: Assess emerging technologies (microwave inertization, ozonation, Artificial Intelligence-enabled reverse logistics) for efficacy and scalability.
- **Environmental monitoring**: Establish surveillance of trial-related pharmaceutical residues in local ecosystems as part of eco-pharmacovigilance.

10. CONCLUSION

The appropriate disposal of investigational products in clinical research encompasses ethical, scientific, regulatory, and environmental dimensions. Effective strategies require:

- **Early integration** of disposal and environmental policies into trial and supply planning;
- **Robust logistics** including participant returns, QA oversight, and cradle-to-grave tracking;

• Use of **validated, environmentally sound destruction methods** with proper documentation and certification;
• **Stakeholder education** and behaviour-change strategies for sites and participants;
• Alignment with **circular economy principles** through take-back programs, digital forecasting, and industry stewardship.

By implementing these approaches, clinical research entities can safeguard participant safety, comply with regulations, and minimize pharmaceutical pollution-promoting sustainability and public trust in clinical science.

REFERENCES:

1. Frontiers in Environmental Science. Minimizing the environmental impact of unused pharmaceuticals: prevention-focused review. 2022.
2. Eisenman D, Swindle S. FDA guidance on shedding and environmental impact in clinical trials involving gene therapy products. Appl Biosaf. 2022;27(3):191–197.
3. ISPE Good Practice Guide: Investigational Medicinal Product Reverse Logistics – Good Returns and Reconciliation Practices. ISPE; Aug 2021.
4. Clinical Studies.in. Return and destruction of supplies in clinical trials: complete compliance guide. Clin Res Made Simple. 2023.
5. NCBI Bookshelf. Final disposition of investigational medicinal products in emergency research response. In: Pharmaceutical Management – Principles and Practice. 2021.
6. Singh K et al. Design and execution of sustainable decentralized clinical trials. Clin Pharmacol Ther. 2023;114.
7. Scientific article: Sustainable management and valorization of antibiotic waste. Chem Eng J. 2024;404:article 138752.
8. Pharmaceutical wastewater and sludge valorization: a review on innovative strategies for energy recovery and waste treatment. Energies. 2024;17(2).
9. Unlocking biogas production potential: evaluating the environmental impact and biodegradability of pharmaceutical and medical wastes. Sigma J Eng Nat Sci. 2024;42(1).
10. Intentions to create green start-ups for collection of unwanted drugs: an empirical study. Sustainability (Switzerland). 2024;16(5).
11. Scientific guideline: emerging trends in eco-friendly pharmaceuticals policy. Explor Res Clin Soc Pharm. 2025;4(1):50-61.
12. Waste Management, Volume 104; solid waste management chapter referencing pharmaceutical disposal costs. Waste Manag. 2023;104:75-96.
13. Lima ML et al. Solid waste management: pharmaceuticals in public health. Waste Manag. 2020;81:168-176.
14. Tabash MI et al. Public health impacts of improper pharmaceutical disposal. Public Health. 2016;138:127-137.
15. NCBI Bookshelf. Management of waste: disposal of radioactive–biological contaminated labware. In: Prudent Practices in the Laboratory. 2011.
16. Environmental Health Perspectives. Anti-infectives in contaminated wastewaters. 2009;117(6):750-604.
17. Oximio insights. IMPs for clinical trials: return, accountability and destruction. 2022.
18. ICH – WHO guidelines on good clinical practice (GCP). Geneva: ICH; 1996.
19. EMA. Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials (draft).
20. FDA: Drug Disposal – take-back options guidance. 2024.
21. European Commission. Directive 2004/10/EC implementing OECD GLP principles. Off J Eur Union. 2004;L50:44–50.
22. OECD Principles of Good Laboratory Practice (GLP) and GLP compliance monitoring. OECD ENV Health & Safety Publications. 2009.
23. Bound JP. Behaviour and environmental threat perceptions in pharmaceutical disposal. Int Encycl Public Health. 2009.
24. Wilkinson JL, Boxall ABA. Pharmaceutical pollution of the world's rivers. Proc Natl Acad Sci U S A. 2022;119(7):e2120730119.
25. Review of removal of pharmaceuticals and PPCPs from wastewater. J Environ Manage. 2016;182.
26. Talanta. Environmental risk assessment of pharmaceutical residues. 2006;69(1):17-21.
27. Boxall et al. Expert stakeholder views on management of human pharmaceuticals in environment. Environ Manag. 2006;38(3):351-61.
28. WHO. Pharmaceuticals in drinking-water. Geneva: WHO; 2012.
29. AP News/Donn J. Tons of released drugs taint U.S. water. AP. 2009.
30. GIZ. Solid Waste Management in Morocco. Deutsche Gesellschaft für Internationale Zusammenarbeit; 2014.
31. Global Fund. Technical brief: sustainable health care waste management. Global Fund; 2022.

32. Global Fund. Technical brief: avoidance, reduction and safe management of healthcare waste, 2020.
33. Environmental persistent pharmaceutical pollutant review Applied Clinical Trials: Lifecycle destruction and paper record considerations.
34. Med Sci Environ review: Environmental risk and market approval for human pharmaceuticals. 2023.
35. LWW 2019: Environmental impacts of expired medicines in India; vulture decline and contamination.
36. BMC Health Services Research 2023: Community pharmacists' awareness of medicine disposal in Palestine.
37. WHO guidelines: Safe disposal in emergencies and normal conditions.
38. Review of effects of pharmaceutical waste on environment and human health (Pharmacophore 2023).
39. EPA: Impact of pharmaceuticals released to the environment. 2024.
40. EPA: How pharmaceuticals enter the environment. 2025.
41. ScienceDirect: Pharmaceuticals and the environment-comprehensive review.
42. PMC: Theme issue on pharmaceutical exposure to wildlife.
43. ResearchGate: Comprehensive environmental impact of pharmaceuticals review.
44. MDPI: Global problem of household pharmaceutical waste disposal. 2022.
45. Adamemberadvantage: Importance of waste segregation. Ad Member Advantage
46. SOP IDS policy: Investigational product destruction procedures, University of Utah. Society for Clinical Research Sites pharmacyservices.utah.edu University of Iowa Healthcare.
47. EMA draft ICH E6(R3) document on investigational product handling.
48. Sciencedirect interview study: Environmental actions in pharmaceutical lifecycle.
49. Delhi-region disposal practices study.
50. Research on behavioral interventions for disposal practices.
51. ExplorationPub review: Effects of pharmaceutical pollutants.
52. EPA Blueprint: 10-step guide to managing pharmaceutical waste.
53. Appliedclinicaltrialsonline: Article on destruction of obsolete records, including IP logs.
54. Stericycle: Controlled substances disposal guidelines.
55. ICH E6(R3) Guideline for Good Clinical Practice. Adopted 6 January 2025. ICH Database, European Medicines Agency (EMA).
56. Oximio guide: Certificates of Destruction importance.